Koza Altin Welcomes UK Supreme Court’s Decision to Dismiss Ipek’s Claims
The UK Supreme Court has delivered a legal blow to businessman Hamdi Akin Ipek this week – overturning an earlier verdict that the English courts have jurisdiction to determine his claims concerning the authority of directors appointed by the Turkish Court. The Supreme Court - which only hears cases of the greatest public or constitutional importance – considered the European law on jurisdiction and all five of the Judges of the Supreme Court determined by unanimous decision that the English Court does not have jurisdiction over Koza Altin and its trustees in relation to the claim concerning the authority of those appointed by the Turkish Court to manage Koza Altin.
The decision is the latest in a series of defeats suffered by Mr Ipek in ongoing litigation over control of Koza Ltd, a UK-based private company wholly owned by Koza Altin, the publicly-listed Turkish conglomerate. This ruling from the UK’s highest court follows an earlier decision of the High Court that the authenticity of documents relied upon by Mr Ipek was "open to very serious doubt". Koza Altin had produced evidence to show that a share purchase agreement created by Mr Ipek to transfer ownership of the Koza Altin group away from Turkey to a UK company owned by Mr Ipek and his family had been backdated.
In a 2017 decision, the Court of Appeal had ruled that the English Court has exclusive jurisdiction to determine whether the authority of trustees, appointed by the Turkish courts to make executive decisions at Koza Altin, should be recognised in England. Mr Ipek claimed that the trustees were appointed in breach of the European Convention on Human Rights and natural justice. However, the Supreme Court has dismissed Mr Ipek’s claim on this issue by finding that the English Court does not have jurisdiction to hear it.
The trustees had been appointed in 2015 by the Turkish Court to safeguard Koza Altin’s assets after serious criminal charges were filed against Mr Ipek who was formerly a senior executive at the Koza companies. No suggestion was made in the 2017 ruling that the trustees had not been appointed entirely lawfully in Turkey.
The trustees’ appointments were made on a temporary basis for the duration of the criminal proceedings which are ongoing in Turkey. Turkey’s Savings Deposit Insurance Fund (TMSF) has since been appointed to oversee the management of the group. The TMSF is an independent and long-established public legal entity in Turkey whose role is to safeguard the interests of depositors and investors.
Mr Ipek's claims against the individual trustees have been dismissed and his claim against Koza Altin regarding the authority of those appointed to run the Koza Altin group has also been dismissed.
Hugo Plowman, the Partner at Mishcon de Reya LLP representing Koza Altin and its former trustees, commented:
“My clients are very pleased with this victory. The Supreme Court has accepted that Turkish officers of a Turkish company who were validly appointed by a Turkish court under Turkish law should not be subject to the exclusive jurisdiction of the English Court. That has been their position all along and it is pleasing that the Supreme Court has finally decided that they were right.
Koza Altin does, of course, accept the English Court’s jurisdiction over the specific issue of English Company Law concerning Mr Ipek’s changes to the Articles of Association of Koza Ltd. My clients argue that Mr Ipek and his brother made changes to the constitution of the English subsidiary unlawfully and with the improper purpose of advancing their own personal interests. We welcome this decision by the Supreme Court which allows us to focus on taking this case to trial and not to be distracted by Mr Ipek’s other claims that have now been dismissed.”
Koza Altin’s case that will continue is that Mr Ipek and Koza Ltd are improperly and unlawfully seeking to prevent Koza Altin from exercising its rights as shareholder of Koza Ltd. Koza Altin is seeking the removal of Mr Ipek as a director of Koza Ltd in order to protect Koza Altin and its assets for the benefit of its shareholders and in accordance with its regulatory obligations. Specifically, the company (Koza Altin) is taking action to ensure that around £60m of shareholders’ capital held by Koza Ltd cannot be improperly taken out of the company and used for Mr Ipek’s personal interests.
The action is taken for the benefit of all of Koza Altin’s shareholders - including funds, banks and other Turkish and international investors who directly own 30% of Koza Altin and indirectly own a majority of 58%. Koza Altin also follows the requirements of the Capital Market Board which is the regulatory authority for the Turkish capital markets.
Mark Leftly / Blair Campbell
+44 (0)20 7250 1446
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
IFF Declares Dividend for Fourth Quarter 201912.12.2019 00:15:00 EET | Press release
Regulatory News: IFF (NYSE:IFF) (Euronext Paris:IFF) (TASE:IFF), a leading innovator of taste, scent and nutrition announced that its Board of Directors has declared a regular quarterly cash dividend of $0.75 per share of its common stock, payable on January 7, 2020 to shareholders of record as of December 27, 2019. Welcome to IFF At IFF (NYSE:IFF) (Euronext Paris:IFF) (TASE:IFF), we’re using Uncommon Sense to create what the world needs. As a collective of unconventional thinkers and creators, we put science and artistry to work to create unique and unexpected scents, tastes, experiences and ingredients for the products our world craves. Learn more at iff.com, Twitter , Facebook, Instagram, and LinkedIn. View source version on businesswire.com: https://www.businesswire.com/news/home/20191211005907/en/ Contact information Michael DeVeau Head of Investor Relations and Communications & Divisional CFO, Scent 212.708.7164 Michael.DeVeau@iff.com
Kite Submits Biologics License Application to U.S. Food and Drug Administration for Company’s Second CAR T Cell Therapy12.12.2019 00:05:00 EET | Press release
Kite, a Gilead Company (Nasdaq: GILD), today announced that it has submitted a Biologics License Application (BLA) to the U.S. Food and Drug Administration (FDA) for the investigational chimeric antigen receptor (CAR) T cell therapy, KTE-X19, for the treatment of adult patients with relapsed or refractory mantle cell lymphoma (MCL). The BLA submission is based on data from the Phase 2 ZUMA-2 trial, which demonstrated an overall response rate of 93 percent, including 67 percent with complete response, as assessed by an Independent Radiologic Review Committee (IRRC) following a single infusion of KTE-X19. In the safety analysis, Grade 3 or higher cytokine release syndrome (CRS) and neurologic events were seen in 15 percent and 31 percent of patients, respectively. No Grade 5 CRS or neurologic events occurred. Detailed findings from this trial were recently presented at the 61st American Society of Hematology (ASH) Annual Meeting & Exposition in Orlando. “There remains a significant need
PTW International Announces Orange Rock Studios, Their Product and Game Development Arm11.12.2019 20:00:00 EET | Press release
Pole to Win International, Ltd. (PTW), the industry-leading video games and tech services outsourcer, today announced the launch of its product and game development arm, Orange Rock Studios. Orange Rock Studios will enhance the service offering of PTW, a gaming industry stalwart with an established and diverse dossier of top-tier clients across multiple verticals. “The time to be disruptive is now,” said Deborah Kirkham, CEO of PTW. “At Orange Rock, we foster future technologies to anchor projects with ingenuity and discipline for generation Y and Z. Together with our clients, we envision and engineer digital experiences.” “Orange Rock is the engine that will build PTW’s future by enabling us to bring each of our existing service lines - Quality Assurance, Customer Support, Audio Production, Localization, and Translation - to the forefront of their fields through cutting edge in-house tool development. We will deliver the creative products that accelerate our industry’s progress toward
Fastly Shares the Most Notable Internet Infrastructure Milestones of 2019, and What 2020 Might Bring for the Expansion of Platform-Independent Computing11.12.2019 19:30:00 EET | Press release
Fastly, Inc. (NYSE: FSLY), provider of a global edge cloud platform, today released its “Behind the Screens” retrospective detailing 2019’s notable milestones in internet infrastructure, from the increased adoption of modernized protocols, to the growth in reach and capacity of global high-speed internet, and more. Fastly’s CTO and co-founder, Tyler McMullen, anticipates that these advancements, combined with the rise of WebAssembly and the extension of code portability across platforms and devices, set the programming world up for achieving broader value from serverless computing. The State of Internet Infrastructure in 2019 This year saw a groundswell of grassroots protocol improvements, sweeping shifts toward encryption due to increased focus on data privacy, and a preview into WebAssembly’s possibilities at the edge, as well as: New satellites that took to the sky and submarine cables that were installed to grow capacity around the globe. Congestion control reimagined through BBR,
Invicro Supports the Alzheimer’s Disease Neuroimaging Initiative11.12.2019 18:37:00 EET | Press release
Invicro LLC, a Konica Minolta Company, today announced funding support for the Alzheimer’s Disease Neuroimaging Initiative (ADNI), and two of their distinguished scientists within the Alzheimer’s biomarkers space, Drs. Roger Gunn and Kenneth Marek, will join the ADNI-Private Partner Scientific Board (PPSB). Invicro is a global provider of imaging biomarkers, core lab services, advanced analytics and software solutions for drug discovery and development. ADNI is a longitudinal multicenter study designed to develop clinical, imaging, genetic, and biochemical biomarkers for the early detection and tracking of Alzheimer’s disease (AD). ADNI’s mission strives to detect AD at the earliest stage possible (pre-dementia) and identify ways to track the disease’s progression with biomarkers, as well as support advances in AD intervention, prevention, and treatment. “Invicro is delighted to support ADNI which plays a central role in the development of biomarkers that enable advances in AD interven
Sevan Elevate Brings Safety and Sustainability to New Heights11.12.2019 17:00:00 EET | Press release
Sevan Multi-Site Solutions, Inc. (Sevan), a global leader in data analytics, surveys, design, program management and construction services, is excited to announce the launch of Sevan Elevate, a program that will reinforce and continuously improve Safety and Sustainability across the company to deliver excellence to people and clients. Safety and Sustainability have been a strategic imperative since 2011 when Sevan was founded by a handful of entrepreneurs, including President and CEO Jim Evans. “Sevan’s tenets are Safety and Sustainability—both of which are woven through every element of the company. It is imperative that all our people—including team members, clients and business partners—return home safely to their loved ones at the end of the day,” Evans said. “With Sevan Elevate, the company is more committed than ever to raise awareness and compliance of Safety and Sustainability throughout the multi-site construction world. We’re not going to change the world overnight, but we ca
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.Visit our pressroom